Clinical trial NCT04263766: The Role of Different Prefrontal Areas in Visual Metacognition
Official title: The Role of Different Prefrontal Areas in Visual Metacognition
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Transcranial Magnetic Stimulation
Metacognition
Prefrontal Cortex
Lead sponsor: Georgia Institute of Technology
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2020-02-11
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: TMS manipulation. Within-subjects design. Each participant will receive TMS to three different sites: DLPFC, aPFC, and a control site.
Primary purpose: BASIC_SCIENCE

Brief summary: The study will use transcranial magnetic stimulation (TMS) to investigate the causal role of different brain regions during visual perception. TMS is a well-established technique used by hundreds of labs in the world. The risks associated with the technique are well understood and can be minimized by strict adherence to established safety guidelines. In the proposed study, the investigators will use TMS to specifically address the topic of how metacognitive evaluation is supported by the two prefrontal areas: the dorsolateral prefrontal cortex (DLPFC) and the anterior prefrontal cortex (aPFC). The data will be collected from healthy adults and will ultimately deepen the investigator's understanding of the mechanisms behind the normal processes related to confidence generation and metacognition.

Detailed description: Participants will complete a task on visual perception and receive TMS in order to assess which regions of the brain are important for confidence generation in perceptual tasks. The task will involve judging the identity of visual stimuli (oriented black-and-white gratings) and providing a confidence rating on the judgment that they performed.

The researchers will deliver TMS to several brain regions such as the anterior prefrontal cortex (aPFC), dorsolateral prefrontal cortex (DLPFC), and a control site. The researchers will then investigate participants' accuracy and confidence levels depending on where TMS was delivered. The researchers expect that aPFC TMS will decrease the metacognitive sensitivity of the participants, whereas DLPFC TMS will decrease their average confidence level. TMS will be delivered time locked to the onset of the stimulus and the researchers will investigate what is the critical period of involvement of a given region.

The TMS protocol is well within the established safety limits. Participants will be required to fill out screening and demographic forms delivered at the Center for Advanced Brain Imaging (CABI). In order to dose appropriately the TMS stimulation, it is necessary to perform motor threshold determination. Motor threshold (MT) is defined as the minimum magnetic flux needed to elicit a visual hand twitch (in the contralateral first dorsal interosseus muscle). MT is the standard in the field for determining the intensity of TMS for each individual to reduce seizure risk. The scalp region producing the largest hand twitch will be identified. At that scalp location, the lowest TMS intensity able to elicit 5 visible twitches in 10 trials at this site will be determined. Individual MT will be used to determine the intensity of stimulation for each individual, as recommended by safety guidelines. This procedure usually takes about 5 minutes and also serves the purpose of acquainting participants to TMS stimulation. In this study, the researchers will use intensities between 100 and 120% of MT, even though the safety guidelines allow for stimulation intensities of at least 130% of MT.

Eligibility criteria: Inclusion Criteria:

* right-handed
* adults 18-40
* with normal or corrected-to-normal vision

Exclusion Criteria:

* history of seizures
* family history of epilepsy
* stroke
* severe headaches
* metal anywhere in the head (excluding the mouth)
* cardiac pacemakers
* current use of medication for neurological or psychiatric conditions

Primary outcomes:
measure: Average Confidence Difference With the 0 ms Condition
timeFrame: 6 months
measure: Average Mratio Difference With the 0 ms Condition
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Atlanta
country: United States
facility: Center for Advance Brain Imaging
state: Georgia
Study officials:
affiliation: Georgia Institute of Technology
name: Dobromir A. Rahnev, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: